Business Context and Reporting Period
Company: Prestige Brands Holdings, Inc. (Prestige Consumer Healthcare Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2008 (Nine months ended December 31, 2008)
Business Overview: The Company markets, sells, and distributes over-the-counter healthcare, personal care, and household cleaning brands to mass merchandisers, drug stores, and supermarkets primarily in the United States and Canada. Operations are divided into three segments: Over-the-Counter Healthcare, Household Cleaning, and Personal Care.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2008 | Nine Months Ended Dec 31, 2008 | Nine Months Ended Dec 31, 2007 |
|---|---|---|---|
| Total Revenues | $80,278 | $241,863 | $246,170 |
| Gross Profit | $42,461 | $127,982 | $127,295 |
| Gross Margin % | 52.9% | 52.9% | 51.7% |
| Operating Income | $19,962 | $61,677 | $66,621 |
| Net Income | $8,018 | $24,321 | $23,568 |
| Diluted EPS | $0.16 | $0.49 | $0.47 |
| Cash from Operating Activities | N/A | $53,347 | $35,306 |
| Total Debt (Long-term + Current) | N/A | $384,338 | $411,225 |
| Cash and Cash Equivalents | N/A | $27,934 | $6,078 (Mar 31, 2008) |
Material Changes vs. Prior Period
- Revenue: For the nine months ended December 31, 2008, total revenues decreased 1.7% to $241.9 million compared to $246.2 million in the prior year. This decline was driven by decreases in the Household Cleaning and Personal Care segments, partially offset by growth in Over-the-Counter Healthcare. International revenues declined 5.8% due to unfavorable foreign currency exchange rates.
- Profitability: Net income increased 3.2% to $24.3 million for the nine-month period. Gross margin improved to 52.9% from 51.7% in the prior year, attributed to favorable sales mix, price increases, and cost reduction programs, despite higher promotional allowances.
- Operating Expenses: Advertising and promotion expenses increased 14.1% to $32.4 million, primarily due to the launch of the "Allergen Block" product line. General and administrative expenses rose 6.7% to $25.6 million, largely due to higher stock-based compensation costs and unfavorable currency translation.
- Debt Reduction: The Company reduced its total indebtedness to $384.3 million from $411.2 million at the beginning of the fiscal year, repaying $24.2 million of the Tranche B Term Loan Facility in excess of required amortization.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Strategy: Management intends to build cash reserves to approximately $30.0 million to enhance liquidity given the current economic environment and credit market uncertainties. Consequently, debt repayments are expected to be modest through March 31, 2009, resuming at higher levels once the reserve target is met.
- Debt Maturity: The $60.0 million Revolving Credit Facility expires in April 2009. The Company intends to replace this facility but notes that credit market conditions could impede refinancing on favorable terms.
- Legal Proceedings:
- Securities Class Action: A consolidated class action lawsuit regarding the Company's 2005 IPO remains pending. The Court ordered notice to be sent to potential class members in January 2009. The Company cannot estimate the potential loss.
- DenTek Litigation: The Company is involved in intellectual property litigation against DenTek Oral Care, Inc. and related parties. Counterclaims have been filed, and the Company is vigorously defending against them.
- Market Risks: The Company faces risks related to inflation (specifically crude oil prices affecting transportation and packaging), concentration of sales (one customer accounted for 26.0% of sales in the nine-month period), and reliance on third-party manufacturers.
Investor Verification Checklist
- Refinancing Risk: Verify the status of the $60 million Revolving Credit Facility expiring in April 2009 and the Company's ability to secure replacement financing in the current credit market.
- Legal Exposure: Monitor developments in the securities class action lawsuit and the DenTek intellectual property litigation for potential settlement costs or judgments.
- Customer Concentration: Assess the impact of the top customer, which represented 26.0% of sales for the nine-month period, on future revenue stability.
- Debt Covenants: Confirm continued compliance with financial covenants (leverage ratio, interest coverage, fixed charge coverage) under the Senior Credit Facility and Senior Subordinated Notes.
- Product Mix: Evaluate the success of the "Allergen Block" launch in sustaining revenue growth within the Over-the-Counter Healthcare segment to offset declines in other categories.